D. Boral Capital initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $32 price target The clinical-stage biotechnology company is advancing a pipeline of next-generation immunotherapies and lead product CTX-009, a bispecific antibody targeting DLL4 and VEGF, has demonstrated an “overwhelming efficacy signal” in a Phase 2 trial for biliary tract cancers, the analyst tells investors. The firm’s model based on CTX-009 applies a probability of success of 30% for CTX-009, which the analyst says “may be conservative as a fast pathway to market exists.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CMPX:
- Compass Therapeutics Appoints New CFO Amid Strategic Moves
- Compass Therapeutics appoints Shin as Chief Financial Officer
- Compass downgrade ‘curious,’ presents upside, says H.C. Wainwright
- Compass Therapeutics downgraded to Market Perform from Outperform at Leerink
- Compass Therapeutics Reports Q3 2024 Financials and Clinical Progress
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
